• 1
    Park YS, Kim SH, Park SK et al. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea. Lung Cancer 2010; 68: 299304.
  • 2
    Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008; 26: 35529.
  • 3
    Ikeda N, Nagase S, Ohira T. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers. Ann. Thorac. Cardiovasc. Surg. 2009; 15: 1449.
  • 4
    Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res. 2005; 11: 61002.
  • 5
    Zamble DB, Mu D, Reardon JT et al. Repair of cisplatin—DNA adducts by the mammalian excision nuclease. Biochemistry 1996; 35: 1000413.
  • 6
    Rosell R. The predictive and prognostic roles of ERCC1 expression and Akin DNA repair genes in non-small-cell lung cancer: M06-01. J. Thorac. Oncol. 2007; 2: S1667.
  • 7
    Fujii T, Toyooka S, Ichimura K et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008; 59: 37784.
  • 8
    Liang J, Lv H, Yao R et al. ERCC1 Asn118Asn polymorphism as predictor for cancer response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Chin Ger J Clin Oncol 2008; 7: 4559.
  • 9
    Takenaka T, Yano T, Kiyohara C et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010; 67: 1017.
  • 10
    Cicchillitti L, Penci R, Di Michele M et al. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol. Cancer Ther. 2008; 7: 20709.
  • 11
    Forde JC, Perry AS, Brennan K et al. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urol. Oncol. 2010. Epub ahead of print; doi: 10.1016/j.urolonc.2010.08.015.
  • 12
    Koh Y, Kim TM, Jeon YK et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann. Oncol. 2009; 20: 141419.
  • 13
    Koh Y, Jang B, Han SW et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J. Thorac. Oncol. 2010; 5: 3205.
  • 14
    Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thorac. Oncol. 2007; 2: 70614.
  • 15
    Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control. Clin. Trials 1996; 17: 3436.
  • 16
    Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006; 355: 98391.
  • 17
    Simon GR, Sharma S, Cantor A et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127: 97883.
  • 18
    Holm B, Mellemgaard A, Skov T et al. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J. Clin. Oncol. 2009; 27: 42549.
  • 19
    Bepler G, Olaussen KA, Vataire AL et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am. J. Pathol. 2011; 178: 6978.
  • 20
    Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007; 356: 8008.
  • 21
    Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 2006; 17: 181825.
  • 22
    Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002; 8: 228691.
  • 23
    Reiman T, Lai R, Veillard AS et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann. Oncol. 2011. Epub ahead of print; doi: 10.1093/annonc/mdr033.
  • 24
    Izutsu N, Maesawa C, Shibazaki M et al. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int. J. Oncol. 2008; 32: 122735.
  • 25
    Park SY, Hong YC, Kim JH et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med. Oncol. 2006; 23: 48998.
  • 26
    Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 31116.
  • 27
    Kalikaki A, Kanaki M, Vassalou H et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 2009; 10: 11823.
  • 28
    Zhou C, Ren S, Zhou S et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn. J. Clin. Oncol. 2010; 40: 95460.
  • 29
    Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 2004; 10: 493943.
  • 30
    Chang PM, Tzeng CH, Chen PM et al. ERCC1 codon 118 C[RIGHTWARDS ARROW]T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 2009; 100: 27883.